myositis: An inflammatory disease involving a pathogenic inflammatory response in the muscle tissue.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
300 |
4. Check minimum number of eventsNone |
300 |
5. Include endpointsNone |
300 |
6. Filter based on genotype QC (FinnGen only) |
293 |
Control definitions (FinnGen only)
- Control exclude
- M13_SYSTCONNECT
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- M33
- Name in latin
- Polymyositis
Similar endpoints
↥List of similar endpoints to
Polymyositis
based on the number of shared cases.
Similar with more cases:
- Dermatopolymyositis (FG)
- Dermatopolymyositis
- Systemic connective tissue disorders
- Autoimmune diseases related-to ILD
- Finngen Rheumatological endpoints
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 2237 | 1327 | 876 |
| Only index persons | 1502 | 917 | 585 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.03 | 0.04 | 0.02 |
| Only index persons | 0.03 | 0.03 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 60.94 | 61.53 | 59.95 |
| Only index persons | 57.28 | 57.97 | 56.19 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 293 | 179 | 114 |
| Unadjusted period prevalence (%) | 0.06 | 0.06 | 0.05 |
| Median age at first event (years) | 55.84 | 55.22 | 56.81 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 300
- Matched controls
- 3000
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M33.2
ICD-10 Finland
Polymyositis
+∞
307.7
263
*
L04AX01
ATC
azathioprine; systemic
49.8
188.1
117
38
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
20.5
159.5
166
171
G72.9
ICD-10 Finland
Myopathy, unspecified
74.4
125.8
69
12
L04AX03
ATC
methotrexate; systemic
13.1
99.1
119
143
M60.9
ICD-10 Finland
Myositis, unspecified
426.2
94.6
90
*
M05BA04
ATC
alendronic acid; oral
11.1
79.7
104
137
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
11.7
74.6
90
106
L04AA06
ATC
mycophenolic acid; systemic
33.8
70.0
46
16
L01BA01
ATC
methotrexate; systemic
19.2
60.4
50
31
H02AB07
ATC
prednisone; oral
7.2
56.1
110
224
P01BA02
ATC
hydroxychloroquine; oral
9.0
55.1
80
117
H02AB06
ATC
prednisolone; systemic
7.7
53.1
241
1038
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
6.1
51.3
203
768
M33.9
ICD-10 Finland
Dermatopolymyositis, unspecified
+∞
48.2
45
*
M33.1
ICD-10 Finland
Other dermatomyositis
+∞
47.1
44
*
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
9.7
45.6
59
74
J99.1*M33.2
ICD-10 Finland
Respiratory disorders in polymyositis
+∞
42.7
40
*
M60.8
ICD-10 Finland
Other myositis
469.0
42.2
41
*
NJ3BG
NOMESCO Finland
MRI examination of extremities with high intensity magnet
128.4
42.0
44
*
M35.9
ICD-10 Finland
Systemic involvement of connective tissue, unspecified
+∞
40.5
38
*
NXL00
NOMESCO Finland
Biopsy of muscle
216.6
37.7
38
*
M35.0
ICD-10 Finland
Sicca syndrome [Sjögren]
61.8
33.1
38
7
NJ3CG
NOMESCO Finland
Extensive MRI examination of extremities with median high magnet
78.8
31.6
35
5
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
7.9
31.5
47
69
L88
ICPC
Rheumatoid/seropositive arthritis
9.2
28.9
37
45
M05BA07
ATC
risedronic acid; oral
9.3
27.6
35
42
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
6.2
26.2
49
91
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.5
24.9
190
985
L04AA01
ATC
[U] ciclosporin
51.2
23.8
28
6
L04AD01
ATC
ciclosporin; systemic
23.0
23.1
33
16
7104A
ICD-9 Finland
Diffuse diseases of connective tissue, Polymyositis
+∞
22.2
21
*
71610
ICD-8 Finland
Polymyositis and dermatomyositis, Polymyositis
+∞
22.2
21
*
M35.1
ICD-10 Finland
Other overlap syndromes
+∞
21.1
20
*
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
4.4
20.4
59
159
J18.9
ICD-10 Finland
Pneumonia, unspecified
3.1
18.8
116
510
NGA20
NOMESCO Finland
Exploration of soft tissue knee or lower leg, open
71.1
17.9
20
*
L28
ICPC
Limited function/disability (L)
3.2
17.7
88
340
UGC12
NOMESCO Finland
Flexible bronchoscopy
4.1
16.1
49
136
M35.3
ICD-10 Finland
Polymyalgia rheumatica
12.2
15.6
28
25
J84.9
ICD-10 Finland
Interstitial pulmonary disease, unspecified
12.2
15.6
28
25
TPH04
NOMESCO Finland
Cathetrisation of vein
3.0
15.6
93
396
A49.9
ICD-10 Finland
Bacterial infection, unspecified
3.7
15.6
56
175
XG410
NOMESCO Finland
Flow-volume spirometry
6.4
15.5
27
46
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.5
15.2
60
199
TGC00
NOMESCO Finland
Bronchial lavation
6.6
14.9
25
41
J99.1
ICD-10 Finland
Respiratory disorders in other diffuse connective tissue disorders
+∞
13.6
13
*
C03CA01
ATC
furosemide; systemic
2.5
13.6
128
679
J84.8
ICD-10 Finland
Other specified interstitial pulmonary diseases
27.2
13.5
18
7
G72.8
ICD-10 Finland
Other specified myopathies
11.3
13.5
25
24
J84.1
ICD-10 Finland
Other interstitial pulmonary diseases with fibrosis
10.4
13.5
26
27
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.6
13.1
113
573
R06.0
ICD-10 Finland
Dyspnoea
2.6
13.0
111
561
L99
ICPC
Musculoskeletal disease other
11.8
12.8
23
21
M33.0
ICD-10 Finland
Juvenile dermatomyositis
+∞
12.6
12
*
Z3226
NOMESCO Finland
Physiotherapist
2.8
12.6
81
355
R4120
NOMESCO Finland
Occupational therapy
4.1
12.2
36
97
ZX120
NOMESCO Finland
Intravenous
3.5
12.0
46
149
R50.9
ICD-10 Finland
Fever, unspecified
3.0
12.0
63
247
C08CA05
ATC
nifedipine; systemic
4.0
11.8
35
95
XG412
NOMESCO Finland
Flow-volume spirometry with bronchospasmolysis
4.4
11.7
31
77
R13
ICD-10 Finland
Dysphagia
3.7
11.7
40
120
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
2.7
11.5
77
342
M32.9
ICD-10 Finland
Systemic lupus erythematosus, unspecified
+∞
11.5
11
*
L19
ICPC
Muscle symptom/complaint NOS
10.2
11.5
22
23
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
3.2
11.4
50
176
R4110
NOMESCO Finland
Physiotherapy
2.4
11.3
108
568
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
5.3
11.2
23
46
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
3.7
11.1
37
109
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
3.4
10.9
42
136
M06.9
ICD-10 Finland
Rheumatoid arthritis, unspecified
5.9
10.8
20
36
WYA30
NOMESCO Finland
Treatment of a patient needing special arrangements
3.6
10.8
38
116
XX9XE
NOMESCO Finland
Other ultrasound examination
22.5
10.8
15
7
A28
ICPC
Limited function/disability NOS
2.7
10.7
69
300
G71.9
ICD-10 Finland
Primary disorder of muscle, unspecified
62.3
10.7
12
*
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
2.9
10.6
55
213
H26.3
ICD-10 Finland
Drug-induced cataract
24.4
10.3
14
6
EBA10
NOMESCO Finland
Operative extraction of tooth
3.2
10.1
43
148
M79.0
ICD-10 Finland
Rheumatism, unspecified
5.4
10.0
20
39
NG4AA
NOMESCO Finland
Lower leg X-ray examination
5.4
10.0
20
39
R4190
NOMESCO Finland
Nutritional therapy
5.3
9.7
20
40
318
Kela drug reimbursment
Teriparatide
56.9
9.7
11
*
H05AA02
ATC
teriparatide; parenteral
56.9
9.7
11
*
Z46.8
ICD-10 Finland
Fitting and adjustment of other specified devices
7.6
9.7
22
31
M05.8
ICD-10 Finland
Other seropositive rheumatoid arthritis
3.8
9.6
31
89
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
2.7
9.6
60
256
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
3.4
9.6
36
115
N28
ICPC
Limited function/disability (N)
11.2
9.4
17
16
A02BC02
ATC
pantoprazole; systemic
2.3
9.2
220
1636
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
3.7
9.2
30
87
B07.9
ICD-10 Finland
Verruca simplex
5.1
9.0
19
39
ND2AA
NOMESCO Finland
Hand and fingers X-ray examination
3.1
8.9
40
142
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
4.4
8.9
23
56
M13.9
ICD-10 Finland
Arthritis, unspecified
3.5
8.8
32
100
N03AX16
ATC
[U] pregabalin
2.3
8.7
86
452
G72.4
ICD-10 Finland
Inflammatory myopathy, not elsewhere classified
+∞
8.4
8
*
NJ3DG
NOMESCO Finland
Very extensive MRI examination of extremities with high intensity magnet
+∞
8.4
8
*
M60.0
ICD-10 Finland
Infective myositis
+∞
8.4
8
*
XG470
NOMESCO Finland
Measurement of diffusion capastity of the lungs
6.6
8.2
20
32
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
2.5
8.1
60
277
ZXX01
NOMESCO Finland
Extent of proceudre, 1 unit
22.7
8.1
11
5
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
2.7
8.1
47
193
WZC10
NOMESCO Finland
Written specialist consultation based on a referral from a dentist or a physician
4.3
7.9
21
52
G62.9
ICD-10 Finland
Polyneuropathy, unspecified
4.4
7.9
20
48
SPAT1083
SPAT
Initiation and monitoring of IV fluid therapy
4.5
7.8
19
44
H05BA01
ATC
calcitonin (salmon synthetic); nasal, parenteral
4.2
7.8
21
53
XA402
NOMESCO Finland
ENMG
6.5
7.7
19
31
NH3AA
NOMESCO Finland
Foot and toes X-ray examination
3.0
7.6
35
126
M62.9
ICD-10 Finland
Disorder of muscle, unspecified
25.8
7.6
10
*
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.4
7.6
61
292
SPAT1229
SPAT
Assessment of need for aid
3.1
7.5
32
110
A41.9
ICD-10 Finland
Sepsis, unspecified
4.6
7.5
18
41
Z50.1
ICD-10 Finland
Other physical therapy
3.3
7.5
29
94
NF1AE
NOMESCO Finland
Hip joint ultrasound examination
8.0
7.5
16
21
XPX04
NOMESCO Finland
Angioscopy
82.0
7.4
8
*
XG466
NOMESCO Finland
Sleep oxymetry
4.3
7.4
19
46
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
2.7
7.4
41
164
J05AB01
ATC
aciclovir; systemic
2.1
7.3
81
442
J99.1*M33.9
ICD-10 Finland
Respiratory disorders in dermatopolymyositis
+∞
7.3
7
*
G73.7*M35.0
ICD-10 Finland
Myopathy in sicca syndrome [Sjögren]
+∞
7.3
7
*
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
2.3
7.3
65
325
L29
ICPC
Musculoskeletal sympt/complt other
3.0
7.3
33
118
C07AB07
ATC
bisoprolol; oral
1.9
7.2
162
1134
R1250
NOMESCO Finland
Evaluation of functional capability
6.3
7.2
18
30
N99
ICPC
Neurological disease other
10.4
7.1
13
13
H02AB04
ATC
methylprednisolone; systemic
2.4
6.9
55
261
M05BX04
ATC
denosumab; parenteral
3.3
6.9
27
88
R4110, ,
SPAT
2.8
6.9
37
145
SAA04
NOMESCO Finland
Special examination of mouth
3.8
6.9
21
58
G71.08
ICD-10 Finland
Other muscular dystrophy
41.0
6.8
8
*
A02BC01
ATC
omeprazole; systemic
2.0
6.8
95
565
XW000
NOMESCO Finland
Bone marrow biopsy
4.0
6.6
19
50
JCA55
NOMESCO Finland
Endoscopic dilatation of oesophagus
10.4
6.6
12
12
WX725
NOMESCO Finland
Noninvasive ventilation
3.5
6.6
23
70
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
5.9
6.6
17
30
Z01.8
ICD-10 Finland
Other specified special examinations
2.1
6.5
75
414
AA1AD
NOMESCO Finland
CT of head and brain
2.0
6.5
93
555
UJF32
NOMESCO Finland
Coloscopy
2.0
6.5
87
508
JN4BD
NOMESCO Finland
Extensive body CT
2.5
6.5
45
201
E27.3
ICD-10 Finland
Drug-induced adrenocortical insufficiency
71.3
6.4
7
*
QBA99
NOMESCO Finland
Other local destruction of skin of trunk
14.7
6.4
10
7
I50.9
ICD-10 Finland
Heart failure, unspecified
2.3
6.4
56
277
FN1AC
NOMESCO Finland
Angiography of heart and/or coronary arteries
2.0
6.3
77
434
A01AB10
ATC
natamycin; local oral
5.3
6.3
18
36
A07AA02
ATC
nystatin; oral
3.0
6.3
28
99
M81.4
ICD-10 Finland
Drug-induced osteoporosis
27.3
6.3
8
*
M05BB03
ATC
alendronic acid and colecalciferol; oral
5.6
6.3
17
32
ZXD30
NOMESCO Finland
Difficulties in perfomrming procedure
3.8
6.1
19
53
M48.0
ICD-10 Finland
Spinal stenosis
2.3
6.1
47
220
H04.10
ICD-10 Finland
Dry eye syndrome
2.4
6.1
44
200
N03AX12
ATC
[U] gabapentin; oral
2.2
6.1
60
312
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
94
11
123.99
183.73
4.1
1.2
9.26
5.61
u/l
1.64
89
11
50
11
54.35
86.18
1.2
1.0
—
—
—
0
0
53
41
15.49
56.89
1.8
1.1
51.30
—
u/ml
—
8
0
47
52
10.53
39.70
1.6
1.2
3.62
3.08
u/ml
—
18
6
50
64
9.18
37.78
2.0
1.3
—
—
—
0
0
41
59
7.89
27.88
1.5
1.6
—
0.01
—
0
8
229
1361
3.88
23.59
20.4
9.1
4.37
4.11
e9/l
1.02
221
1195
201
1165
3.20
20.19
14.0
6.6
1.21
1.22
mmol/l
0.53
180
998
191
1077
3.13
20.12
12.1
5.5
1.21
1.22
mmol/l
0.86
182
973
91
365
3.14
17.12
2.5
1.8
—
—
—
0
0
55
170
3.74
15.54
4.8
3.5
183.76
191.54
ng/l
0.06
49
159
26
45
6.23
14.72
11.3
9.1
189.14
139.11
iu/ml
—
7
9
29
57
5.53
14.42
1.7
1.8
—
—
—
0
0
247
1780
3.19
14.01
13.0
3.8
15.61
12.14
mm/h
3.18
241
1630
23
18
13.73
13.65
1.3
1.2
—
—
—
0
0
23
18
13.73
13.65
1.3
1.2
—
—
—
0
0
161
953
2.49
13.48
3.0
2.2
80.16
77.79
nmol/l
0.47
154
843
23
19
13.00
13.34
1.3
1.2
—
—
—
0
0
23
19
13.00
13.34
1.3
1.2
—
—
—
0
0
23
19
13.00
13.34
1.3
1.2
—
—
—
0
0
67
258
3.06
13.23
2.4
1.8
—
—
—
0
0
29
62
5.07
13.13
1.8
1.7
—
—
—
0
0
23
41
5.99
12.62
1.8
1.8
—
—
—
0
0
23
41
5.99
12.62
1.8
1.8
—
—
—
0
0
130
718
2.43
12.42
4.8
3.1
1151.95
1231.50
ng/l
0.10
119
615
26
54
5.18
12.14
1.3
1.2
—
—
—
0
0
33
84
4.29
12.09
1.9
2.2
—
—
—
0
0
21
36
6.20
11.97
1.6
1.4
—
—
—
0
0
49
169
3.27
11.57
2.4
1.5
—
—
—
0
0
33
87
4.14
11.54
3.0
2.7
—
—
—
0
0
165
1035
2.32
11.51
7.4
4.3
33.98
35.59
g/l
2.70
160
977
62
255
2.80
10.73
2.4
1.7
—
—
—
0
0
22
46
5.08
10.18
1.5
1.6
—
—
—
0
0
174
1154
2.21
10.14
5.5
3.6
0.00
0.00
estimate
0.50
33
227
20
39
5.42
9.98
1.3
1.3
—
—
—
0
0
129
769
2.19
9.74
6.1
3.2
48.89
31.98
u/l
1.84
124
731
19
37
5.41
9.49
1.3
1.2
224.38
246.19
u/ml
0.09
13
21
115
664
2.19
9.33
4.6
3.0
0.38
0.43
e6/l
0.12
92
481
185
1283
2.15
9.30
9.1
6.3
10.28
11.22
umol/l
0.96
179
1208
171
1157
2.11
9.10
7.6
4.9
0.00
0.00
estimate
-0.00
34
213
89
471
2.26
8.88
6.3
3.7
220.23
194.29
ng/l
0.08
81
381
21
48
4.63
8.76
1.7
1.8
—
—
—
0
0
171
1171
2.07
8.65
5.6
3.7
0.00
0.00
estimate
-0.00
35
205
16
16
10.49
8.63
1.4
1.2
2.20
—
u/ml
—
5
0
13
8
16.90
8.63
1.9
2.3
—
—
—
0
0
58
259
2.54
8.42
17.5
7.1
10.39
12.23
kpa
2.62
53
249
58
259
2.54
8.42
17.6
7.1
5.33
5.12
kpa
0.69
53
247
16
17
9.87
8.38
1.6
1.2
133.67
—
u/ml
—
6
0
18
39
4.85
7.99
1.6
1.6
—
—
—
0
0
65
317
2.34
7.76
3.1
2.3
22.62
22.63
%
0.00
53
274
57
263
2.44
7.69
17.9
7.1
2.02
1.16
mmol/l
0.56
48
212
78
414
2.19
7.60
3.6
2.6
0.70
1.22
e6/l
1.61
47
233
18
28
6.77
7.53
2.3
1.8
—
—
—
0
0
57
271
2.36
7.18
2.5
3.0
7.07
9.37
umol/l
0.60
46
239
42
175
2.63
6.98
2.4
2.5
13.18
20.01
au/ml
—
5
9
73
395
2.12
6.70
1.5
1.2
62.76
41.98
iu/ml
0.34
27
124
43
185
2.55
6.70
19.3
7.3
11.11
9.87
mmol/l
0.38
43
177
160
1137
1.87
6.60
18.2
13.0
1.42
1.24
inr
0.81
42
342
16
26
6.44
6.56
1.8
1.8
—
—
—
0
0
16
26
6.44
6.56
1.8
1.8
—
—
—
0
0
45
200
2.47
6.55
3.2
2.2
18.28
7.24
ug/l
2.02
39
177
71
384
2.11
6.51
4.1
2.8
2.68
2.78
e6/l
0.04
42
206
87
513
1.98
6.28
1.2
1.2
1.02
1.34
u/ml
0.24
17
149
13
17
7.94
6.19
1.1
1.1
—
—
—
0
0
98
605
1.92
6.17
4.1
2.7
370.05
8804.02
umol/l
3.30
92
521
12
14
8.87
6.11
1.1
1.2
—
—
—
0
0
12
15
8.28
5.89
2.3
1.1
—
—
—
0
0
14
26
5.59
5.29
1.9
2.0
—
—
—
0
0
14
26
5.59
5.29
1.1
1.1
—
—
—
0
0
16
44
3.78
5.28
1.5
1.3
—
—
—
0
0
16
44
3.78
5.28
1.5
1.3
—
—
—
0
0
88
555
1.83
5.05
2.7
2.0
2.95
3.17
mg/l
0.43
78
479
31
131
2.52
5.01
1.5
1.4
—
—
—
0
0
13
24
5.61
4.97
1.8
2.1
—
—
—
0
0
15
33
4.73
4.94
1.8
1.7
—
—
—
0
0
16
38
4.39
4.90
1.1
1.6
—
—
—
0
0
179
1389
1.72
4.89
11.0
4.5
6.48
6.71
mmol/l
1.10
170
1296
45
227
2.16
4.87
2.3
2.4
518.73
32.84
u/l
0.49
37
191
110
752
1.73
4.75
2.9
2.5
53.96
61.15
u/l
0.54
104
687
84
531
1.81
4.75
2.3
1.7
1.34
1.25
mg/l
0.11
67
426
15
35
4.46
4.70
1.1
1.6
—
—
—
0
0
90
583
1.78
4.68
1.6
1.5
20.21
21.51
nmol/l
0.41
79
490
22
81
2.85
4.62
1.4
1.2
—
—
—
0
0
13
27
4.98
4.55
1.4
1.3
—
—
—
0
0
22
82
2.82
4.53
1.4
1.2
—
—
—
0
0
134
983
1.66
4.36
2.1
2.0
94.56
95.36
pmol/l
0.06
75
487
15
38
4.10
4.36
1.7
1.6
—
—
—
0
0
64
382
1.86
4.32
1.3
1.2
52.96
12.02
u/ml
0.67
18
147
72
448
1.80
4.25
1.7
1.7
1137.16
1176.75
nmol/l
0.13
57
334
116
825
1.66
4.23
4.1
3.3
2.33
2.35
mmol/l
1.05
105
725
14
36
4.03
4.05
5.2
2.8
5.19
4.87
e9/l
0.16
14
36
30
139
2.29
3.99
2.2
1.6
—
—
—
0
0
131
973
1.61
3.96
3.4
2.6
164.66
115.08
ug/l
1.13
123
896
14
37
3.92
3.95
5.6
3.4
65.71
61.08
%
0.70
14
37
19
71
2.79
3.90
1.7
1.2
—
—
—
0
0
6
5
12.20
3.78
1.2
1.0
—
—
—
0
0
27
123
2.31
3.73
1.4
1.3
—
—
—
0
0
8
13
6.29
3.52
1.8
1.5
—
—
—
0
0
126
949
1.57
3.48
5.4
3.6
88.37
31.56
ng/l
3.01
104
666
10
22
4.66
3.46
1.5
1.8
—
—
—
0
0
10
22
4.66
3.46
1.5
1.8
—
—
—
0
0
10
22
4.66
3.46
1.5
1.8
—
—
—
0
0
21
89
2.46
3.40
2.8
1.9
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
17
65
2.71
3.36
5.5
2.1
0.31
0.32
u/ml
—
10
30
15
55
2.82
3.20
2.1
1.3
—
—
—
0
0
8
16
5.10
3.07
1.0
1.0
—
—
—
0
0
13
45
2.97
3.06
1.4
1.4
—
—
—
0
0
5
5
10.14
2.99
1.0
1.2
—
—
—
0
0
70
475
1.62
2.94
2.4
2.9
2.46
2.46
mmol/l
0.11
59
420
15
58
2.67
2.92
1.3
1.3
—
—
—
0
0
7
14
5.09
2.74
2.1
3.1
972.43
775.36
u/ml
—
7
14
6
10
6.10
2.71
1.0
1.1
—
—
—
0
0
260
2376
1.71
2.57
35.4
13.5
20.17
23.56
mg/l
1.36
248
1854
6
11
5.54
2.55
1.8
2.0
—
—
—
0
0
6
11
5.54
2.55
1.8
2.0
—
—
—
0
0
6
11
5.54
2.55
1.8
2.0
—
—
—
0
0
7
16
4.45
2.49
1.7
1.7
—
—
—
0
0
7
16
4.45
2.49
1.7
1.7
—
—
—
0
0
8
22
3.71
2.38
1.1
1.0
—
—
—
0
0
10
34
3.01
2.30
1.2
1.1
—
—
—
0
0
70
504
1.51
2.25
6.9
3.9
1.02
1.02
kg/l
0.07
13
75
13
54
2.47
2.23
1.1
1.1
—
—
—
0
0
5
9
5.63
2.22
1.0
1.1
—
—
—
0
0
7
19
3.75
2.16
1.3
1.2
—
—
—
0
0
6
14
4.35
2.16
1.5
1.1
—
—
—
0
0
6
14
4.35
2.16
1.3
1.5
0.98
0.96
g/l
—
6
14
205
2268
0.70
2.16
4.7
4.1
1.66
1.28
mmol/l
3.83
193
2069
181
1562
1.40
2.13
4.3
3.1
51.01
49.64
u/l
0.11
175
1449
17
82
2.14
2.11
2.6
1.7
—
—
—
0
0
9
31
2.96
2.09
1.0
1.1
—
—
—
0
0
15
69
2.24
2.08
1.2
1.4
324.89
252.51
ug/g
—
9
37
7
20
3.56
2.06
1.0
1.0
—
—
—
0
0
7
21
3.39
1.97
1.0
1.1
—
—
—
0
0
11
45
2.50
1.95
4.5
2.6
15.22
16.57
%
—
5
22
5
11
4.60
1.95
1.2
1.5
1.82
1.60
g/l
—
5
11
7
22
3.23
1.89
1.3
1.5
—
—
—
0
0
216
2353
0.71
1.89
5.0
4.5
1.34
1.49
mmol/l
7.00
205
2169
8
28
2.91
1.87
1.9
2.0
—
—
—
0
0
6
17
3.58
1.84
1.3
3.4
—
—
—
0
0
13
60
2.22
1.80
1.3
1.7
—
—
—
0
0
9
191
0.45
1.80
2.1
1.8
—
—
—
0
0
12
54
2.27
1.76
3.3
2.1
114.00
132.92
g/l
—
7
37
5
13
3.89
1.72
4.2
1.8
48.20
60.10
ug/l
—
5
13
6
19
3.20
1.67
1.0
1.2
—
—
—
0
0
201
1801
1.35
1.66
4.8
4.0
15.23
14.79
pmol/l
1.73
188
1617
224
2047
1.37
1.59
39.8
16.5
15.36
15.16
%
0.25
224
2015
11
50
2.25
1.59
1.1
1.3
—
—
—
0
0
6
20
3.04
1.59
2.7
2.4
—
—
—
0
0
8
33
2.46
1.55
1.4
1.2
—
—
—
0
0
37
253
1.53
1.52
6.2
3.4
—
—
—
0
0
220
2367
0.74
1.51
4.9
4.6
4.76
4.68
mmol/l
0.54
208
2190
9
38
2.41
1.47
1.1
1.1
—
—
—
0
0
28
181
1.60
1.46
7.1
2.7
4.81
4.36
kpa
0.69
28
174
5
16
3.16
1.44
1.2
1.5
—
—
—
0
0
5
16
3.16
1.44
1.2
1.5
—
—
—
0
0
109
909
1.31
1.44
6.1
3.7
—
—
—
0
0
7
29
2.45
1.40
1.1
1.0
—
—
—
0
0
128
1098
1.29
1.35
3.7
2.4
—
—
—
0
0
79
635
1.33
1.34
7.1
3.8
0.00
0.00
estimate
-0.00
34
208
19
114
1.71
1.31
1.0
1.0
—
—
—
0
0
6
25
2.43
1.25
2.2
1.6
—
—
—
0
0
6
25
2.43
1.25
2.2
1.6
—
—
—
0
0
5
19
2.66
1.22
1.2
1.5
—
—
—
0
0
6
26
2.33
1.19
2.2
1.6
—
—
—
0
0
6
26
2.33
1.19
2.2
1.6
—
—
—
0
0
6
26
2.33
1.19
2.2
1.6
—
—
—
0
0
6
26
2.33
1.19
2.2
1.6
—
—
—
0
0
11
58
1.93
1.13
1.2
1.3
—
—
—
0
0
227
2406
0.77
1.13
5.3
5.2
2.86
2.76
mmol/l
1.05
218
2212
12
66
1.85
1.10
2.3
1.4
—
—
—
0
0
9
49
1.86
0.99
1.8
1.5
—
—
—
0
0
87
737
1.25
0.98
3.6
3.8
9.59
9.05
mg/mmol
0.05
53
463
6
27
2.25
0.94
4.3
3.7
—
—
—
0
0
6
29
2.09
0.90
1.2
1.2
—
—
—
0
0
36
279
1.33
0.80
1.4
1.6
1.39
1.50
%
0.64
29
242
0
27
0.00
0.78
0.0
1.4
—
—
—
0
0
0
27
0.00
0.78
0.0
1.4
—
—
—
0
0
0
27
0.00
0.78
0.0
1.4
—
—
—
0
0
11
173
0.62
0.78
1.9
1.7
—
—
—
0
0
9
58
1.57
0.70
1.7
1.8
—
—
—
0
0
76
658
1.21
0.70
1.6
1.6
1.68
1.34
mmol/l
2.05
68
557
65
556
1.22
0.67
3.2
2.2
—
—
—
0
0
44
361
1.26
0.66
1.4
1.4
—
—
—
0
0
228
2179
1.19
0.63
5.8
4.8
1.89
2.47
mu/l
0.51
219
1964
0
21
0.00
0.60
0.0
1.1
—
—
—
0
0
6
37
1.63
0.56
2.2
2.7
—
9.91
—
0
8
26
205
1.29
0.54
3.0
2.9
82.38
62.46
ml/min/173m2
—
8
83
9
61
1.49
0.54
1.7
1.3
—
—
—
0
0
10
69
1.46
0.45
1.7
1.6
—
—
—
0
0
0
17
0.00
0.41
0.0
4.2
—
—
—
0
0
219
2255
0.89
0.35
6.4
5.8
40.13
39.99
mmol/mol
0.09
208
2086
144
1382
1.08
0.25
3.1
2.8
—
—
—
0
0
16
190
0.83
0.24
1.5
1.8
—
—
—
0
0
8
105
0.76
0.21
3.1
3.4
10.25
1451.73
u/ml
—
8
90
45
414
1.10
0.20
2.8
3.0
0.69
0.75
ug/l
0.34
33
273
33
362
0.90
0.18
2.0
1.4
—
—
—
0
0
9
82
1.10
0.15
1.2
1.6
—
—
—
0
0
73
705
1.05
0.10
4.6
4.7
3.97
2.21
ug/l
0.55
67
633
5
46
1.09
0.09
1.2
1.4
—
—
—
0
0
231
2333
0.96
0.09
5.2
4.6
5.80
6.00
mmol/l
1.73
212
2142
261
2629
0.94
0.09
50.5
20.4
39.72
40.07
%
0.51
241
2463
33
313
1.06
0.08
4.5
4.3
28.85
31.96
%
0.99
26
199
228
2267
1.02
0.03
27.9
13.1
86.39
79.99
ml/min/173m2
3.40
205
1853
30
293
1.03
0.01
7.6
6.4
—
—
—
0
0
15
154
0.97
0.00
2.1
2.4
11.23
13.91
nmol/l
1.13
15
143
56
564
0.99
0.00
3.6
4.4
22.12
21.34
%
0.14
27
266
6
62
0.97
0.00
1.0
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.0
—
1.18
—
0
6
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint M13_POLYMYO and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_POLYMYO | 2.097 [1.76, 2.5] | < 0.001 |
| Birth year | 0.994 [0.99, 1.0] | 0.186 |
During the follow-up period (1.1.1998 — 31.12.2019), 247 out of 750 females with M13_POLYMYO died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_POLYMYO | 2.472 [2.02, 3.03] | < 0.001 |
| Birth year | 0.987 [0.98, 1.0] | 0.006 |
During the follow-up period (1.1.1998 — 31.12.2019), 217 out of 521 males with M13_POLYMYO died.
Mortality risk
Mortality risk for people of age
years, who have M13_POLYMYO.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.119% | 0.47% |
| 5 | 1.131% | 2.714% |
| 10 | 2.947% | 6.901% |
| 15 | 5.887% | 13.095% |
| 20 | 10.067% | 21.454% |
Relationships between endpoints
↥Index endpoint: M13_POLYMYO – Polymyositis
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data